Table 2.
Tumor responses for the patients in matched cohort
| Response | Overall tumor | Intrahepatic tumor | Vascular tumor thrombus | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| TKI-I group (n = 51) |
TKI group (n = 51) |
P | TKI-I group (n = 51) |
TKI group (n = 51) |
P | TKI-I group (n = 42) |
TKI group (n = 36) |
P | |||
| CR, n (%) | 1 (2.1) | 1 (2.1) | 2 (4.2) | 1 (2.1) | 13 (36.1) | 0 (0.0) | |||||
| PR, n (%) | 32 (66.7) | 15 (31.3) | 31 (64.6) | 16 (33.3) | 16 (44.4) | 5 (12.5) | |||||
| SD, n (%) | 10 (20.8) | 16 (33.3) | 11 (22.9) | 17 (35.4) | 4 (11.1) | 22 (55.0) | |||||
| PD, n (%) | 5 (10.4) | 16 (33.3) | 4 (8.3) | 14 (29.2) | 3 (8.3) | 13 (32.5) | |||||
| ORR, % | 68.8 | 33.3 | 0.001 | 68.8 | 35.4 | 0.001 | 80.6 | 12.5 | < 0.001 | ||
| DCR, % | 89.6 | 66.7 | 0.007 | 91.7 | 70.8 | 0.009 | 91.7 | 67.5 | 0.010 | ||
TKI-I tyrosine kinase inhibitor combined with iodine-125 seed brachytherapy, TKI tyrosine kinase inhibitor, CR complete response, PR partial response, SD stable disease, PD progressive disease, ORR objective response rate, DCR disease control rate